{"id":1402,"date":"2024-04-03T17:30:39","date_gmt":"2024-04-03T15:30:39","guid":{"rendered":"https:\/\/remeds.org\/?p=1402"},"modified":"2025-09-10T08:53:27","modified_gmt":"2025-09-10T06:53:27","slug":"huidagene-moving-towards-clinical-trials","status":"publish","type":"post","link":"https:\/\/remeds.org\/hr\/2024\/04\/03\/huidagene-moving-towards-clinical-trials\/","title":{"rendered":"HuidaGene: Kretanje prema klini\u010dkim ispitivanjima"},"content":{"rendered":"<p>U velja\u010di 2024., David Covini, predsjednik DupMECP2, posjetio je inovativnu biotehnolo\u0161ku tvrtku HuidaGene Therapeutics u \u0160angaju. Posjet je pru\u017eio uzbudljiv uvid u budu\u0107nost tretmana za sindrom duplikacije MECP2 (MDS).<\/p>\n\n\n\n<p>Predvo\u0111ena dr. Alvinom Lukom, izvr\u0161nim direktorom u HuidaGene, tvrtka je na \u010delu razvoja revolucionarne CRISPR tehnologije koja bi mogla revolucionirati \u017eivote djece pogo\u0111ene MDS-om.&nbsp;<\/p>\n\n\n\n<p>Posjet je bio nevjerojatna prilika da se iz prve ruke svjedo\u010di vrhunskim objektima i kreativnom okru\u017eenju koje poti\u010de takva inovativna istra\u017eivanja. Radni prostor \u010dak uklju\u010duje zid za penjanje, promi\u010du\u0107i dinami\u010dnu i kreativnu radnu atmosferu.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img fetchpriority=\"high\" decoding=\"async\" width=\"1920\" height=\"1080\" src=\"https:\/\/remeds.org\/wp-content\/uploads\/2025\/07\/Newsletter-1-edited.png\" alt=\"\" class=\"wp-image-3480\" srcset=\"https:\/\/remeds.org\/wp-content\/uploads\/2025\/07\/Newsletter-1-edited.png 1920w, https:\/\/remeds.org\/wp-content\/uploads\/2025\/07\/Newsletter-1-edited-300x169.png 300w, https:\/\/remeds.org\/wp-content\/uploads\/2025\/07\/Newsletter-1-edited-1024x576.png 1024w, https:\/\/remeds.org\/wp-content\/uploads\/2025\/07\/Newsletter-1-edited-768x432.png 768w, https:\/\/remeds.org\/wp-content\/uploads\/2025\/07\/Newsletter-1-edited-1536x864.png 1536w, https:\/\/remeds.org\/wp-content\/uploads\/2025\/07\/Newsletter-1-edited-18x10.png 18w\" sizes=\"(max-width: 1920px) 100vw, 1920px\" \/><\/figure>\n\n\n\n<p>Alvin i njegova medicinska direktorica za MDS, dr. Gloria Tang, predstavili su detalje CRISPR-Cas13 tehnologije za ure\u0111ivanje RNA za sindrom duplikacije MECP2, nazvanu HG204. Obe\u0107avaju\u0107i podaci i preliminarni rezultati iz studija toksi\u010dnosti na primatima koji nisu ljudi doveli su do uzbudljivog razvoja. Klini\u010dko ispitivanje MDS-a tvrtke, prvotno planirano za po\u010detak u drugoj polovici 2024., ve\u0107 je dobilo odobrenje eti\u010dkog povjerenstva dviju bolnica s planom upisa pacijenata s MDS-om prije kraja godine.<\/p>\n\n\n\n<p>Ovo je fantasti\u010dna vijest za MDS zajednicu. Nadolaze\u0107e klini\u010dko ispitivanje HG204 za MDS, nazvano \"HERO,\" isprva \u0107e lije\u010diti najmanje 4 pacijenta koji \u0107e biti pomno pra\u0107eni godinu dana. Prva faza ovog ispitivanja bit \u0107e provedena u Kini. Daljnji upis pacijenata u Kini ovisit \u0107e o prvim preliminarnim rezultatima intervencijske studije.&nbsp;<\/p>\n\n\n\n<p class=\"translation-block\">HuidaGene je ve\u0107 napravio zna\u010dajne korake u regulatornom odobrenju, osiguravaju\u0107i dvije oznake FDA (Oznaka za rijetke pedijatrijske bolesti (RPDD) i Oznaka za lijekove bez vlasnika (ODD)) za HG204 za lije\u010denje sindroma duplikacije MECP2. Tako\u0111er su zapo\u010deli kontakt s FDA i EMA za daljnje studije u SAD-u i Europi.<\/p>\n\n\n\n<p>Prilika za osobni susret s Alvinom i Glorijom bila je privilegija. Uzbu\u0111eni smo \u0161to smo dio ovog putovanja i radujemo se obavje\u0161tavanju na\u0161e zajednice o napretku ove potencijalno \u017eivotno mijenjaju\u0107e tehnologije.<\/p>","protected":false},"excerpt":{"rendered":"<p>In February 2024, David Covini, President of DupMECP2, visited the innovative biotech company HuidaGene Therapeutics in Shanghai. The visit provided an exciting glimpse into the future for a treatment for MECP2 duplication syndrome (MDS). Led by Dr. Alvin Luk, CEO at HuidaGene, the Company is at the forefront of developing a groundbreaking CRISPR technology that [&hellip;]<\/p>\n","protected":false},"author":73,"featured_media":3480,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jf_save_progress":"","footnotes":""},"categories":[12,10,9],"tags":[],"class_list":["post-1402","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-crispr","category-cure","category-research"],"_links":{"self":[{"href":"https:\/\/remeds.org\/hr\/wp-json\/wp\/v2\/posts\/1402","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/remeds.org\/hr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/remeds.org\/hr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/remeds.org\/hr\/wp-json\/wp\/v2\/users\/73"}],"replies":[{"embeddable":true,"href":"https:\/\/remeds.org\/hr\/wp-json\/wp\/v2\/comments?post=1402"}],"version-history":[{"count":4,"href":"https:\/\/remeds.org\/hr\/wp-json\/wp\/v2\/posts\/1402\/revisions"}],"predecessor-version":[{"id":3561,"href":"https:\/\/remeds.org\/hr\/wp-json\/wp\/v2\/posts\/1402\/revisions\/3561"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/remeds.org\/hr\/wp-json\/wp\/v2\/media\/3480"}],"wp:attachment":[{"href":"https:\/\/remeds.org\/hr\/wp-json\/wp\/v2\/media?parent=1402"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/remeds.org\/hr\/wp-json\/wp\/v2\/categories?post=1402"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/remeds.org\/hr\/wp-json\/wp\/v2\/tags?post=1402"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}